Vistagen Therapeutics, Inc. (VTGN)

Market Cap	88.97M
Revenue (ttm)	646,000
Net Income (ttm)	-55.78M
Shares Out	30.68M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	283,110
Open	2.885
Previous Close	2.860
Day's Range	2.860 - 3.030
52-Week Range	1.900 - 3.790
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2025

About VTGN

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN
• Website: https://www.vistagen.com

Financial Performance

In 2024, Vistagen Therapeutics's revenue was $486,000, a decrease of -54.32% compared to the previous year's $1.06 million. Losses were -$51.42 million, 75.1% more than in 2023.